ABVC BioPharma Receives $100,000 Milestone Payment from OncoX BioPharma, Strengthening Oncology Partnership

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced the receipt of a $100,000 milestone payment from OncoX BioPharma, Inc., marking a significant step in their strategic licensing agreement initiated in 2024. This payment brings the total licensing revenue for ABVC and its subsidiaries to $1.046 million, highlighting the commercial viability and potential of their oncology platform.

The collaboration between ABVC and OncoX is focused on the development and global commercialization of botanical therapeutics in oncology. This partnership not only validates the commercial value of ABVC's late-stage oncology platform but also supports ongoing efforts to expand OncoX's therapeutic focus and enhance its market presence. The agreement includes potential future milestone and royalty-based payments, contributing to ABVC's long-term revenue outlook.

Dr. Uttam Patil, ABVC's Chief Executive Officer, emphasized the significance of this milestone payment, stating it reflects the shared belief in the potential for new product and market opportunities. Yen Wen Pin, CEO of OncoX BioPharma, also expressed excitement about the next stage of collaboration, viewing the payment as an investment in long-term innovation aimed at bringing novel botanical-based treatments to global markets.

The strategic impact of this partnership is evident in ABVC's financial performance, with a 234% year-over-year increase in revenue in 2024 and a 77% improvement in earnings per share. The total potential value of disclosed licensing agreements and related products is estimated at over $959 million, indicating strong market interest in ABVC's drug development model.

With the global cancer therapeutics market projected to reach $393.61 billion by 2032, growing at a CAGR of 9.2%, the collaboration between ABVC and OncoX is poised to capitalize on this expanding market. The partnership is expected to drive future regulatory filings and commercialization opportunities in oncology, offering promising prospects for both companies and their stakeholders.